at iap

AT-IAP is an effective dual antagonist of XIAP and cIAP1.

IAPligand 5 functions as an IAP ligand and is utilized in the synthesis of PROTACERαDegrader-2.

PROTAC pan-IAP degrader-1 (Compound 9) is a pan- IAP degrader PROTAC . PROTAC pan-IAP degrader-1 degrades XIAP , cIAP1 and cIAP2 with DC 50 s of 0.7, 2.4, and 6.2 nM in MM.1S cells, respectively [1] .

Anti-Mouse CD47/IAP Antibody (MIAP301) is a monoclonal antibody inhibitor targeting mouse CD47/IAP. It enhances macrophage phagocytosis and immune cell infiltration, restores myeloid cell phagocytic function, and alleviates B-cell suppression. It can be used in research on cancer, inflammation, and infectious diseases.

Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) is an IgG1 monoclonal antibody specifically directed against mouse, rat, and human CD47/IAP. It effectively blocks CD47-mediated signaling to enhance macrophage phagocytic activity, promote immune cell infiltration into tissues, potentially interfere with wound healing processes, and support experimental investigations in oncology and inflammatory disease models, including but not limited to breast cancer research and studies of intestinal mucosal repair mechanisms.

Survivin (baculoviral inhibitor of apoptosis IAP repeat-containing protein-5) is a member of the IAP gene family, which has been implicated in both inhibitions of apoptosis and mitosis regulation1. Survivin is one of the most uniformly up-regulated genes

PROTAC ERα Degrader-2 is composed of a cIAP1 ligand binding group, a linker, and an estrogen receptor α (ERα) binding group, serving as an ERα degrader. It achieves maximal ERα degradation in human mammary tumor MCF7 cells at a concentration of 30 μM. Degradation inducers that utilize cIAP1 are referred to as specific and non-genetic IAP-dependent protein erasers (SNIPERs)[1].

PROTAC RAR Degrader-1, an RAR degrader, consists of a cIAP1 ligand binding group, a linker, and an RAR ligand binding group. It achieves maximal RAR degradation at a concentration of 30 μM in HT1080 cells. Degradation inducers that utilize cIAP1 are known as specific and non-genetic IAP-dependent protein erasers (SNIPERs)[1].

CST 530 is a monovalent IAP antagonist. It induces cIAP1 and cIAP2 autodegradation in MM.1S cells (cIAP1 degradation at 0.1 μM and cIAP2 degradation at 1 μM after 16 hours). CST 530 reduces cell viability in multiple cancer cell lines including SUDHL6, MOLM13, and HEL (IC50 values ​​of 170 nM, 420 nM, and 450 nM, respectively).

Xevinapant hydrochloride (AT-406 HCl) , an orally active antagonist of multiple inhibitor of apoptosis proteins(IAP), inhibits progression of human ovarian Y binding to XIAP-BIR3, cIAP1-BIR3 and cIAP2-BIR3 with Ki of 66.4 nM, 1.9 nM, and 5.1 nM, 50- to 100-fold higher affinities than the Smac AVPI peptide.

Xevinapant (Debio-1143) is a potent Smac mimetic and an antagonist of IAP (inhibitor of apoptosis protein via E3 ubiquitin ligase), binding to XIAP-BIR3, cIAP1-BIR3 and cIAP2-BIR3 with Ki of 66.4 nM, 1.9 nM, and 5.1 nM, 50- to 100-fold higher affinities than the Smac AVPI peptide. Phase 1.